A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE014 (NLD) · Dr. Moreau
consented 2022-12-15
AEs
4
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-04-14 (study day 103); relationship: Y
moderate
assessed
Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-04-19 (study day 108); relationship: N
moderate
assessed
Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-04-21 (study day 110); relationship: not assessed
moderate
assessed
Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-04-23 (study day 112); relationship: not assessed
Data queries
No data queries.